Alnylam: Waiting For Regulatory Updates In March
Alnylam awaits FDA decisions on Amvuttra & Fitusiran next month, poised to boost revenue, profitability, and share growth.
hemophilianewstoday2d
Antibody therapy Mim8 seen effective in hemophilia A children
Antibody therapy Mim8 was found to be safe and effective for controlling bleeds in children with hemophilia A in a Phase 3 ...
uniQure/ CSL Behring's Hemophilia Gene Therapy Shows Sustained Efficacy and Safety At Four Years
CSL Limited (OTC:CSLLY) and uniQure Inc (NASDAQ:QURE) announced the four-year results from the pivotal HOPE-B study ...
Healthline3d
How to Make an Emergency Plan for Hemophilia B
Hemophilia B is a genetic condition that limits your blood’s ability to clot. Without prompt treatment, it can become a life threatening emergency. Creating a plan can help you better manage ...
Medscape29d
Gene Therapy in Hemophilia: High Hopes and Costs, Low Uptake
As many as 33,000 men in the United States are estimated to have hemophilia. In recent years, they’ve benefited from newer medications that are more powerful and convenient than the traditional ...
FierceBiotech7d
Novo Nordisk adds pediatric data to bulging bag of evidence on near-approval hemophilia A prospect
Novo Nordisk has bolstered the case for its near-approval hemophilia A drug candidate Mim8, linking the prospect to ...
Hemophilia Treatment Market Valuation is Projected to Reach US$ 21.48 Billion by 2033 | Astute Analytica
Growing advancements in haemophilia treatment underscore a significant shift toward targeted and long-lasting therapeutic ...
BioSpace6d
Novo’s Bispecific for Hemophilia Aces Phase III Pediatric Trial
Novo Nordisk’s bispecific antibody Mim8 prevented bleeding events and caused no adverse safety events in the Phase III ...
Pharm Exec3d
Mim8 Demonstrates Promising Results in Pediatric Patients with Hemophilia A
Data from the Phase III FRONTIER3 trial found that 98% of caregivers prefer Mim8 for hemophilia A over other treatments.